Cholinergic and Dopaminergic Alterations in Nigrostriatal Neurons Are Involved in Environmental Enrichment Motor Protection in a Mouse Model of Parkinson’s Disease

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Molecular Neuroscience

• Publication date

  2016-09-22

• Fields of study

  Medicine, Environmental Science

• Identifiers
  DOI 10.1007/s12031-016-0831-7PMID 27660217
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Medicinal plant Combretum leprosum mart ameliorates motor, biochemical and molecular alterations in a Parkinson's disease model induced by MPTP.

  2016influential reference
• Cholinergic Mesopontine Signals Govern Locomotion and Reward through Dissociable Midbrain Pathways.

  2016influential reference
• Neuroprotective effects of caffeine in MPTP model of Parkinson's disease: A (13)C NMR study.

  2016cited by this paper
• Chronic MPTP treatment produces hyperactivity in male mice which is not alleviated by concurrent trehalose treatment.

  2015cited by this paper
• Absence of Glia Maturation Factor Protects Dopaminergic Neurons and Improves Motor Behavior in Mouse Model of Parkinsonism

  2015cited by this paper
• Behavioural, biochemical and molecular changes induced by chronic crack-cocaine inhalation in mice: The role of dopaminergic and endocannabinoid systems in the prefrontal cortex.

  2015cited by this paper
• Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease.

  2015cited by this paper
• Nigral dopamine loss induces a global upregulation of presynaptic dopamine D1 receptor facilitation of the striatonigral GABAergic output.

  2015cited by this paper
• Activity of Monoamine Oxidase in the Nigrostriatal System at Presymptomatic and Early Symptomatic Stages of Parkinsonism in Mice

  2015cited by this paper
• Neuroprotective effect of lycopene against MPTP induced experimental Parkinson's disease in mice.

  2015cited by this paper
• Timing in reward and decision processes

  2014influential reference
• Multiphasic Modulation of Cholinergic Interneurons by Nigrostriatal Afferents

  2014cited by this paper
• Striatal cholinergic interneuron regulation and circuit effects

  2014influential reference
• Involvement of Cholinergic System in Hyperactivity in Dopamine-Deficient Mice

  2014influential reference
• In the right place at the right time: visualizing and understanding mRNA localization

  2014cited by this paper
• Nobiletin treatment improves motor and cognitive deficits seen in MPTP-induced Parkinson model mice.

  2014cited by this paper
• Juvenile methylphenidate reduces prefrontal cortex plasticity via D3 receptor and BDNF in adulthood

  2014cited by this paper
• Enhancement of cognitive function in models of brain disease through environmental enrichment and physical activity.

  2013influential reference
• Cholinergic Dysfunction in Parkinson’s Disease

  2013cited by this paper
• Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.

  2012cited by this paper
• Neuron NeuroResource The Local Transcriptome in the Synaptic Neuropil Revealed by Deep Sequencing and High-Resolution Imaging

  2012cited by this paper
• Roles of the M1 Muscarinic Acetylcholine Receptor Subtype in the Regulation of Basal Ganglia Function and Implications for the Treatment of Parkinson's Disease

  2012influential reference
• Reduced calcium/calmodulin‐dependent protein kinase II activity in the hippocampus is associated with impaired cognitive function in MPTP‐treated mice

  2012cited by this paper
• Enriched environment promotes similar neuronal and behavioral recovery in a young and aged mouse model of Parkinson's disease.

  2011cited by this paper
• Parkinson's disease: The syndrome, the pathogenesis and pathophysiology

  2009cited by this paper
• History of falls in Parkinson disease is associated with reduced cholinergic activity

  2009influential reference
• Detection and Quantification of Neurotransmitters in Dialysates

  2009cited by this paper
• The neuropathological basis for depression in Parkinson's disease.

  2009cited by this paper
• Enrich the environment to empower the brain.

  2009influential reference
• Environmental toxins and Parkinson's disease: what have we learned from pesticide-induced animal models?

  2009cited by this paper
• Genetic factors involved in the pathogenesis of Parkinson's disease.

  2008cited by this paper
• The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats.

  2007cited by this paper
• Pharmacotherapy for Parkinson's Disease

  2007cited by this paper
• Enriched environment improves motor function in intact and unilateral dopamine-depleted rats.

  2006cited by this paper
• Novel pharmacological targets for the treatment of Parkinson's disease

  2006cited by this paper
• Enriched environments, experience-dependent plasticity and disorders of the nervous system

  2006cited by this paper
• The discovery of dopamine deficiency in the parkinsonian brain.

  2006cited by this paper
• A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.

  2006cited by this paper
• Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man

  2005cited by this paper
• Environmental enrichment in adulthood eliminates neuronal death in experimental Parkinsonism.

  2005cited by this paper
• The MPTP model of Parkinson's disease.

  2005cited by this paper
• Choline Transporter 1 Maintains Cholinergic Function in Choline Acetyltransferase Haploinsufficiency

  2004cited by this paper
• Behavioural and neurochemical effects of phosphatidylserine in MPTP lesion of the substantia nigra of rats.

  2004cited by this paper
• A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function.

  2004cited by this paper
• Aberrant Patterning of Neuromuscular Synapses in Choline Acetyltransferase-Deficient Mice

  2003cited by this paper
• Inhibition of Calpains Prevents Neuronal and Behavioral Deficits in an MPTP Mouse Model of Parkinson's Disease

  2003cited by this paper
• Enriched Environment Confers Resistance to 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine and Cocaine: Involvement of Dopamine Transporter and Trophic Factors

  2003cited by this paper
• Parkinson's Disease Mechanisms and Models

  2003cited by this paper
• D1 Dopamine Receptor Supersensitivity in the Dopamine-Depleted Striatum Results from a Switch in the Regulation of ERK1/2/MAP Kinase

  2002cited by this paper
• Roles of neurotransmitter in synapse formation: development of neuromuscular junctions lacking choline acetyltransferase.

  2002cited by this paper
• Chemical neuroanatomy of the basal ganglia--normal and in Parkinson's disease.

  2001cited by this paper
• Levodopa prolongs life expectancy and is non-toxic to substantia nigra.

  2001cited by this paper
• Cholinergic Neuronal Modulation Alters Dopamine D2Receptor Availability In Vivo by Regulating Receptor Affinity Induced by Facilitated Synaptic Dopamine Turnover: Positron Emission Tomography Studies with Microdialysis in the Conscious Monkey Brain

  2000cited by this paper
• Early Parkinson’s Disease

  2000influential reference
• Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice.

  1999cited by this paper
• Enhancement of D1 dopamine receptor - mediated locomotor stimulation in M(4) musca - rinic acetylcho

  1999cited by this paper
• Biochemical aspects of Parkinson's disease

  1998cited by this paper
• Cognitive changes in mice following moderate MPTP exposure.

  1998cited by this paper
• Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 5,7-dihydroxytryptamine on the locomotor activity and striatal amines in C57BL/6 mice.

  1996cited by this paper
• Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA.

  1995cited by this paper
• Differential effect of systemic administration of bromocriptine and L-dopa on the release of acetylcholine from striatum of intact and 6-OHDA-treated rats.

  1993influential reference
• Molecular basis of human MAO A and B.

  1991cited by this paper
• Effects of MPTP on locomotor activity in mice.

  1990cited by this paper
• Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications.

  1988cited by this paper
• Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice.

  1984influential reference
• Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors

  1984cited by this paper
• Choline and cholinergic neurons.

  1983cited by this paper
• Social grouping cannot account for cerebral effects of enriched environments.

  1978cited by this paper

• Proteomic Analysis of Substantia Nigra Reveals Molecular Insights Into the Neuroprotection Effect of Rosmarinic Acid Treatment in MPTP‐Induced Mouse Model of Parkinson's Disease

  2025cites this paper
• Diosgenin derivative ML5 attenuates MPTP-induced neuronal impairment via regulating AMPK/PGC-1α-mediated mitochondrial biogenesis and fusion/fission.

  2024cites this paper
• Efficacy of invasive and non-invasive methods for the treatment of Parkinson's disease: Nanodelivery and enriched environment.

  2023cites this paper
• Biochemical and behavioral effects of rosmarinic acid treatment in an animal model of Parkinson's disease induced by MPTP.

  2022cites this paper
• Molecular mechanisms underlying the neuroprotection of environmental enrichment in Parkinson’s disease

  2022influential citation
• Environmental Enrichment Protects Against Sepsis-Associated Encephalopathy-Induced Learning and Memory Deficits by Enhancing the Synthesis and Release of Vasopressin in the Supraoptic Nucleus

  2022cites this paper
• Is SGSH heterozygosity a risk factor for early‐onset neurodegenerative disease?

  2021cites this paper
• Poly (I:C)-induced maternal immune activation modifies ventral hippocampal regulation of stress reactivity: prevention by environmental enrichment

  2021cites this paper
• From the Gut to the Brain and Back: Therapeutic Approaches for the Treatment of Network Dysfunction in Parkinson's Disease

  2020cites this paper
• Neurobehavioral Changes Arising from Early Life Dopamine Signaling Perturbations.

  2020cites this paper
• Behavioral, Biochemical and Molecular Characterization of a Parkinson’s Disease Mouse Model Using the Neurotoxin 2′-CH3-MPTP: A Novel Approach

  2018influential citation
• Neuroprotective effect of crocin on substantia nigra in MPTP-induced Parkinson’s disease model of mice

  2018cites this paper
• Diosgenin Attenuates Lipopolysaccharide-Induced Parkinson’s Disease by Inhibiting the TLR/NF-κB Pathway

  2018cites this paper
• Environmental enrichment cognitive neuroprotection in an experimental model of cerebral ischemia: biochemical and molecular aspects

  2018cites this paper
• Enriched Physical Environment Attenuates Spatial and Social Memory Impairments of Aged Socially Isolated Mice

  2018cites this paper
• Chemical profiling analysis of Maca using UHPLC-ESI-Orbitrap MS coupled with UHPLC-ESI-QqQ MS and the neuroprotective study on its active ingredients

  2017cites this paper
• The Neuroprotective Effects of Experience on Cognitive Functions: Evidence from Animal Studies on the Neurobiological Bases of Brain Reserve.

  2017cites this paper
• Review on the neuroprotective effects of environmental enrichment in models of Parkinson’s disease

  2016influential citation